Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in

Status Withdrawn

Clinical Trial Summary

Raltegravir not only has a unique mechanism of action, but may also have other unique effects on suppression of viral replication, viral reservoir, and immune reconstitution in blood and other important compartments. This may in part be due to the pharmacokinetics of Raltegravir in blood and gut tissue. Efavirenz will be the comparator antiretroviral drug in this study, with both drugs being used as part of a three-drug regimen with tenofovir and emtricitabine.

The primary objectives are to determine differences in the effects of 2 anti-retroviral regimens, Raltegravir + Truvada versus Atripla, with respect to:

1. Viral load in plasma, genital tract (vaginal secretions), and gut (by in situ hybridization).

2. Latent viral reservoir (pro-viral DNA) in the peripheral blood and genital tract.

3. Immune effects (CD4/CD8 immunophenotypes) in gut and PBMCs and plasma cytokine profiles.

The secondary objective is to determine the pharmacokinetics of Raltegravir in blood and gut tissue; relative tissue/compartment penetration compared to Efavirenz.

Clinical Trial Description

This is a phase III, prospective, randomized (1:1), multicenter, open label study comparing the effects of two HAART regimens:

- Arm A: Raltegravir 400 mg PO BID + TDF/FTC (Truvada, 300/200 mg) One PO Daily

- Arm B: Efavirenz + TDF/FTC (Atripla) Once PO Daily

The following local sites: Mt. Sinai, Rush University Medical Center, Stroger Hospital, University of Chicago and University of Illinois will work together to enroll 10 eligible women meeting all eligibility criteria (5 per study arm) over a one year time period. These 10 women will be randomized 1:1 to receive either TDF/FTC + Raltegravir or TDF/FTC + Efavirenz (Atripla). There will be 2 baseline evaluations prior to initiation of study therapy. Subjects will be followed for 48 weeks after initiation of study treatment. ;

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

HIV-1 Infections

Clinical Trial Details

NCT number	NCT00984152
Study type	Interventional
Source	Rush University Medical Center
Contact
Status	Withdrawn
Phase	Phase 3
Start date	June 2011
Completion date	December 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01013415` - CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients	Phase 1
Active, not recruiting	`NCT02923713` - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV	Phase 2
Completed	`NCT01151319` - Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults	Phase 1
Completed	`NCT01138605` - TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV	Phase 2
Completed	`NCT01078233` - Observational Data Analysis in EuroSIDA (MK-0518-058)
Recruiting	`NCT02593409` - HIV PrEP Priming of Immune Effectors	Phase 4
Completed	`NCT00557245` - Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples	Phase 3
Completed	`NCT00799058` - A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States	Phase 1/Phase 2
Completed	`NCT01159275` - Lopinavir (LPV) Dose Reduction	Phase 1/Phase 2
Completed	`NCT01281813` - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV	Phase 3
Completed	`NCT01078246` - Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
Active, not recruiting	`NCT03027297` - TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV	Phase 3
Completed	`NCT01033760` - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)	Phase 3
Completed	`NCT01139905` - Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children	Phase 2
Completed	`NCT00830804` - Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults	Phase 2
Completed	`NCT01074931` - Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women — ICE-002

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms